Text Size

An ocular toxicity study of Cravit ophthalmic solution 0.5% in monkeys by single injections into the anterior chamber and vitreous body of the eye

Hosoi K., Sasaki M., Kawazu K., Ikuse T.


  • 2010
  • Folia Japonica de Ophthalmologica Clinica
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Preclinical development

  • Affiliations

    Research and Development Division, Santen Pharmaceutical Co., Ltd., Japan; Safety Research Center, Ina Research Inc., Japan

Related Publications

Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.


STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators


Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022